Consumer Protection

Estratest

Result: $16.5 million settlement
Year: 2010

Yarrington v. Solvay Pharmaceuticals, Inc.

In March 2010, the Court granted final approval to a $16.5 million settlement of a false advertising class action lawsuit against Solvay Pharmaceuticals. Lieff Cabraser served as Co-Lead Counsel, representing purchasers of Estratest – a hormone replacement drug.

The complaint alleged that Solvay deceptively marketed Estratest as an FDA-approved drug when in fact Estratest was not approved by the FDA. The settlement provided refunds to consumers for up to 30% of the purchase price paid for Estratest. In addition, $8 million of the settlement was allocated to fund programs and activities related to women’s health concerns at medical schools throughout the nation.
Trademark Notice

Estratest and Estratest H.S. are registered marks of Solvay Pharmaceuticals, Inc. These marks are used for informational purposes only. Lieff Cabraser is not affiliated with Solvay Pharmaceuticals, Inc.